Document Detail

Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response.
MedLine Citation:
PMID:  12759556     Owner:  NLM     Status:  MEDLINE    
Nitric oxide (NO) is produced from its precursor L-arginine by the enzyme NO synthase (NOS), which includes at least three distinct isoforms - neuronal (nNOS), endothelial, and inducible NOS. Recent studies have implicated NOS in the mechanism that underlies the therapeutic efficacy of antidepressant medication. In addition, major depressive disorder (MDD) patients were found to have significantly higher plasma nitrate concentrations than normal subjects, an index of NO production, in comparison to normal subjects. In a population-based association study, we tested the hypothesis that the nNOS C276T polymorphism confers susceptibility to MDD. We also examined the association between this polymorphism and therapeutic fluoxetine response in 114 MDD patients who underwent a 4-week fluoxetine treatment. The results demonstrate that the nNOS variants are found at similar frequencies in MDD patients and healthy control subjects. Further, we did not discover any genetic variants that influenced the fluoxetine response in MDD patients treated with fluoxetine. Our findings suggest that this nNOS C276T polymorphism does not play a major role in the susceptibility to, or fluoxetine response in, MDD. However, the association between other NOS variants and MDD or antidepressant response, including sexual dysfunction, may warrant further investigation.
Younger W-Y Yu; Tai-Jui Chen; Ying-Chieh Wang; Ying-Jay Liou; Chen-Jee Hong; Shih-Jen Tsai
Related Documents :
2724536 - Clinical significance of exercise-induced negative u-waves in patients with anterior my...
4061656 - Effect of adh on chloride reabsorption in the loop of henle of the brattleboro rat.
7556486 - Regulation of outflow rate and resistance in the perfused anterior segment of the bovin...
17402406 - The physiological responses to simulated race tests on a track and on a treadmill in st...
21556736 - Evaluation of the inflammatory response to two different intensities of exercise in ind...
10076146 - Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony af...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neuropsychobiology     Volume:  47     ISSN:  0302-282X     ISO Abbreviation:  Neuropsychobiology     Publication Date:  2003  
Date Detail:
Created Date:  2003-05-21     Completed Date:  2003-07-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7512895     Medline TA:  Neuropsychobiology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  137-40     Citation Subset:  IM    
Copyright Information:
Copyright 2003 S. Karger AG, Basel
Yu's Psychiatric Clinic, Kaohsiung, Taipei, Taiwan, ROC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / therapeutic use*
Depressive Disorder, Major / drug therapy,  enzymology,  epidemiology
Fluoxetine / therapeutic use*
Gene Expression / genetics*
Gene Frequency
Middle Aged
Nitric Oxide Synthase / blood,  genetics*,  metabolism*
Nitric Oxide Synthase Type I
Polymerase Chain Reaction
Polymorphism, Genetic / genetics*
Reg. No./Substance:
0/Antipsychotic Agents; 54910-89-3/Fluoxetine; EC protein, human; EC Oxide Synthase; EC Oxide Synthase Type I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  VNTR polymorphism of tyrosine hydroxylase gene and schizophrenia in the Korean population.
Next Document:  Diffusion tensor magnetic resonance imaging of disruption of regional white matter in schizophrenia.